Uncategorized

Replimune melanoma drug wins support of FDA panel

Published

on

The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version